<div><p><b>Background: </b>An unbiased ‘genome-first’ approach has the potential to expand the understanding of common coding and predicted loss-of-function (pLOF) variants associated with non-alcoholic fatty liver disease (NAFLD). Utilizing this approach, we aimed to uncover the functionality of pathogenic variants in <em>TM6SF2</em>.</p>
<div><p><b>Background: </b>Autoimmune hepatitis is a serious chronic liver disease with immune disorders, histological lesions and liver dysfunction, with a gradually increasing prevalence. Yet the cellular and molecular mechanisms of immune dysregulation in AIH are poorly understood.</p>
<div><p><b>Background: </b>Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by inflammation, bile duct proliferation, and hepatic fibrosis, with a high risk for liver cancer. Multi-drug resistance 2-deficient (Mdr2<sup>-/-</sup>) mice have been widely used as a PSC model. These mice spontaneously develop fibrosis as early as 6-8 weeks and liver tumors at 10-12 months.
<div><p><b>Background:<a href="The pathophysiology of ascites in cirrhosis entails vasodilatation with the consequential activation of sympathetic nervous system and renin-angiotensin-aldosterone system, leading to retention of sodium and water. Dapagliflozin, a sodium glucose linked transporter-2 inhibitor, induces natriuresis and is beneficial in patients with heart failure. We hypothesised that a similar natriuretic effect may improve mobilization of ascites in patients with cirrhosis.
<div><p><b>Background: </b>Baveno VII was proposed for non-invasive identification of clinically significant portal hypertension. However, a substantial proportion of patients is classified in the grey zone (i.e., liver stiffness 15-24.9 kPa and/or platelet count <150 ×10<sup>9</sup>/L). We aimed to evaluate the risk and predictors of hepatic decompensation in grey zone patients and determine the prognostic role of spleen stiffness measurement (SSM).</p>
<div><p><b>Background: </b>The existing hepatocellular carcinoma (HCC) risk scores have modest accuracy and most are specific to chronic hepatitis B. In this study, we developed and validated a liver stiffness-based machine learning algorithm (ML) for prediction and risk stratification of HCC in various chronic liver diseases (CLDs).</p>
<div><p><b>Background:</p> </b><p><span style="font-weight: 400;">Single-cell technologies address the critical issue of tumor heterogeneity in hepatocellular carcinoma (HCC), but face challenges such as complex cell isolation, need for fresh samples, and limited genomic coverage from low DNA content. To overcome these obstacles, we developed a robust workflow for single-nucleus DNA sequencing from frozen HCC tissue, utilizing a custom amplicon panel to elucidate genetic events in HCC clonal evolution.</span></p>
<div><p><b>Background:</p> </b><p>Increased intestinal permeability is one of the multiple hits in the pathogenesis of non-alcoholic steatohepatitis (NASH). Bile salt hydrolase (BSH) is a gut bacterial enzyme that hydrolyzes conjugated bile acids (BAs) into unconjugated BAs. Our previous study reported that inhibition of BSH with a gut-restricted small molecule inhibitor, AAA-10, increased conjugated BAs and prevented the development of intestinal permeability and liver steatosis in an early onset, diet-induced rat steatosis model.
<div><p><b>Background: </b>Due to socioeconomic and healthcare access challenges, safety-net patients with liver disease face substantial disadvantages. Little is known about which factors – including psychosocial factors – impact listing for liver transplantation (LT) among the safety-net population.</p>
<div><p><strong>Background</strong>: Anticoagulation (AC) is the mainstay of thromboprophylaxis for stroke prevention in atrial fibrillation (AF) and is recommended. Cirrhosis is a risk factor for AF development; hence, AF is common in patients with cirrhosis. The hemostatic pathways in cirrhosis are imbalanced which makes their response to anticoagulation unpredictable. While Direct-Oral Anticoagulants (DOACs) are shown to be safe and effective in patients with AF without cirrhosis, they are hardly studied in patients with cirrhosis.